capecitabine has been researched along with Heart Diseases in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajo, D; Duplancic, D; Gavran, I; Meter, M | 1 |
| Chen, L; Chou, C; Li, C; Ngorsuraches, S; Qian, J | 1 |
| Chen, G; Dong, C; Li, W; Peng, J; Qiu, M; Wang, C; Wang, F; Wu, Q; Yu, H; Yuan, Y; Zhang, J; Zhang, M; Zhao, Q; Zhou, W; Zhu, B | 1 |
| Brell, JM; Carver, JR; Denlinger, CS; Dimond, EP; Kircher, SM; Ky, B; O'Neill, A; Upshaw, JN; Wagner, LI | 1 |
| Nielsen, DL; Polk, A; Vaage-Nilsen, M; Vistisen, K | 1 |
| Bhuva, N; Buckley, A; Harrison, M; Kelly, C; Saunders, M | 1 |
| Azamfirei, L; Comsulea, M; Gurzu, S; Jung, I; Kadar, Z; Molnar, C | 1 |
| Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D | 1 |
| Baeksgaard, L; Jensen, SA; Petersen, LN; Reiter, L; Sørensen, JB | 1 |
| Cool, M; Deboever, G; Hiltrop, N; Lambrecht, G | 1 |
| Ernst, A; Grem, JL; Quinn, MG; Saif, MW; Thomas, RR | 1 |
| Barry, S; Cohen, A; Debourdeau, P; Teixeira, L; Tournigand, C | 1 |
| Kahlert, S; Konecny, G; Rueckert, S; Ruehl, I; Untch, M | 1 |
| Jensen, SA; Sørensen, JB | 1 |
| Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S | 1 |
| Iwase, S; Kitamura, K; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D | 1 |
| Kallistratos, MS; Karabelis, A; Kopterides, P; Kosmas, C; Mylonakis, N; Skopelitis, H; Syrios, J; Tsavaris, N | 1 |
| Barriuso, J; Belda, C; Brunello, A; Casado, E; Chiappori, A; de Castro, J; Feliu, J; González-Barón, M; Sereno, M | 1 |
| Diasio, RB; Ledbetter, L; Saif, MW; Tomita, M | 1 |
| Abt, M; Blum, JL; Hoff, PM; Osterwalder, B; Van Cutsem, E | 1 |
5 review(s) available for capecitabine and Heart Diseases
| Article | Year |
|---|---|
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
Topics: Capecitabine; Deoxycytidine; Fluorouracil; Heart Diseases; Humans; Prospective Studies; Retrospective Studies | 2013 |
Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Heart Diseases; Humans; Neoplasms; Quinazolines; Retrospective Studies; Thiophenes | 2013 |
Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cardiovascular Agents; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Heart Diseases; Humans | 2013 |
[Cardiotoxicity of 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Coronary Thrombosis; Coronary Vessels; Deoxycytidine; Electrocardiography; Fluorouracil; Heart; Heart Diseases; Humans; Myocarditis | 2004 |
Cardiac toxicity: old and new issues in anti-cancer drugs.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Aromatase Inhibitors; Capecitabine; Deoxycytidine; ErbB Receptors; Fluorouracil; Heart Diseases; Humans; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Taxoids | 2008 |
2 trial(s) available for capecitabine and Heart Diseases
| Article | Year |
|---|---|
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Heart Diseases; Humans; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2006 |
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Heart Diseases; Humans; Infusions, Intravenous; Japan; Middle Aged; Trastuzumab; Treatment Outcome | 2008 |
13 other study(ies) available for capecitabine and Heart Diseases
| Article | Year |
|---|---|
An unusual case of acute myopericarditis after the first dose of capecitabine: Need for new cardioprotective strategies and risk stratification.
Topics: Capecitabine; Cardiotoxicity; Female; Fluorouracil; Heart Diseases; Humans; Middle Aged; Risk Assessment | 2021 |
Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Decision Support Techniques; Female; Fluorouracil; Heart Diseases; Humans; Machine Learning; Male; Middle Aged; Predictive Value of Tests; Risk Assessment; Risk Factors; SEER Program; Time Factors; Treatment Outcome | 2022 |
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; China; Female; Fluorouracil; Heart Diseases; Humans; Incidence; Male; Middle Aged; Neoplasms; Prospective Studies; Risk Assessment; Young Adult | 2018 |
Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotoxicity; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fluorouracil; Follow-Up Studies; Heart Diseases; Humans; Incidence; Neoplasms; Prognosis; United States | 2019 |
Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman.
Topics: Acute Disease; Adenocarcinoma; Adult; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Capecitabine; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Enteritis; Fatal Outcome; Fatty Liver; Female; Fluorouracil; Heart Diseases; Humans; Multiple Organ Failure; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pancreaticoduodenectomy; Pancreatitis, Chronic | 2013 |
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Substitution; Fluorouracil; Heart Diseases; Humans; Irinotecan; Middle Aged; Quinazolines; Thiophenes | 2014 |
[Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Heart; Heart Diseases; Humans; Isosorbide Dinitrate; Nitroglycerin; Prodrugs; Risk Factors; Vasodilator Agents | 2010 |
Cardiac toxicity associated with capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diagnosis, Differential; Electrocardiography; Fluorouracil; Heart Diseases; Humans; Male; Middle Aged; Prodrugs; Rectal Neoplasms | 2003 |
A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Heart Diseases; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Patient Selection; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Atherosclerosis; Capecitabine; Comorbidity; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Heart Diseases; Humans; Kidney Diseases; Male; Middle Aged; Nitroglycerin; Retrospective Studies; Risk Factors; Vasodilator Agents | 2006 |
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Electrocardiography; Female; Fluorouracil; Head and Neck Neoplasms; Heart; Heart Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Prospective Studies | 2008 |
Capecitabine-related cardiotoxicity: recognition and management.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Heart Diseases; Humans; Incidence; Male; Middle Aged; Prodrugs; Rectal Neoplasms | 2008 |
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Heart; Heart Diseases; Humans; Incidence | 2002 |